CN107001457A - 用于治疗血管性眼病的方法和制剂 - Google Patents
用于治疗血管性眼病的方法和制剂 Download PDFInfo
- Publication number
- CN107001457A CN107001457A CN201580063632.5A CN201580063632A CN107001457A CN 107001457 A CN107001457 A CN 107001457A CN 201580063632 A CN201580063632 A CN 201580063632A CN 107001457 A CN107001457 A CN 107001457A
- Authority
- CN
- China
- Prior art keywords
- ang
- antibody
- vegf antagonist
- eye
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 218
- 230000002792 vascular Effects 0.000 title claims description 69
- 239000000203 mixture Substances 0.000 title claims description 58
- 238000009472 formulation Methods 0.000 title description 34
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 203
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 203
- 239000005557 antagonist Substances 0.000 claims abstract description 162
- 239000003112 inhibitor Substances 0.000 claims abstract description 110
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims description 158
- 239000008194 pharmaceutical composition Substances 0.000 claims description 99
- 238000011282 treatment Methods 0.000 claims description 90
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 63
- 230000027455 binding Effects 0.000 claims description 48
- 239000000427 antigen Substances 0.000 claims description 46
- 102000036639 antigens Human genes 0.000 claims description 46
- 108091007433 antigens Proteins 0.000 claims description 46
- 239000003814 drug Substances 0.000 claims description 44
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 42
- 208000030533 eye disease Diseases 0.000 claims description 42
- 239000012634 fragment Substances 0.000 claims description 42
- 239000003795 chemical substances by application Substances 0.000 claims description 39
- 210000001525 retina Anatomy 0.000 claims description 33
- 208000007135 Retinal Neovascularization Diseases 0.000 claims description 32
- 239000007924 injection Substances 0.000 claims description 31
- 238000002347 injection Methods 0.000 claims description 31
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 30
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 210000004204 blood vessel Anatomy 0.000 claims description 26
- 230000008859 change Effects 0.000 claims description 25
- 238000001990 intravenous administration Methods 0.000 claims description 25
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 24
- 229930006000 Sucrose Natural products 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 24
- 239000005720 sucrose Substances 0.000 claims description 24
- 239000011780 sodium chloride Substances 0.000 claims description 21
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 20
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 20
- 210000001210 retinal vessel Anatomy 0.000 claims description 20
- 239000003381 stabilizer Substances 0.000 claims description 20
- 239000000872 buffer Substances 0.000 claims description 19
- 239000001488 sodium phosphate Substances 0.000 claims description 18
- 235000011008 sodium phosphates Nutrition 0.000 claims description 18
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 18
- 239000002253 acid Substances 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 238000007920 subcutaneous administration Methods 0.000 claims description 16
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 239000003599 detergent Substances 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 14
- 239000012929 tonicity agent Substances 0.000 claims description 14
- 201000011190 diabetic macular edema Diseases 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- 108091008605 VEGF receptors Proteins 0.000 claims description 12
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 210000001367 artery Anatomy 0.000 claims description 11
- 230000037396 body weight Effects 0.000 claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 11
- 229940068977 polysorbate 20 Drugs 0.000 claims description 11
- 230000002829 reductive effect Effects 0.000 claims description 11
- 201000005667 central retinal vein occlusion Diseases 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 230000002207 retinal effect Effects 0.000 claims description 10
- 108010048036 Angiopoietin-2 Proteins 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 9
- 108060003951 Immunoglobulin Proteins 0.000 claims description 8
- 102000018358 immunoglobulin Human genes 0.000 claims description 8
- 210000003462 vein Anatomy 0.000 claims description 8
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 7
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 7
- 230000002491 angiogenic effect Effects 0.000 claims description 7
- 230000008485 antagonism Effects 0.000 claims description 7
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 6
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 200000000007 Arterial disease Diseases 0.000 claims description 5
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims description 5
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 5
- 208000028922 artery disease Diseases 0.000 claims description 5
- 208000001344 Macular Edema Diseases 0.000 claims description 4
- 206010025415 Macular oedema Diseases 0.000 claims description 4
- 201000010230 macular retinal edema Diseases 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 229950008882 polysorbate Drugs 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000000185 sucrose group Chemical group 0.000 claims description 4
- 239000000539 dimer Substances 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 4
- 102000009075 Angiopoietin-2 Human genes 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 229910021529 ammonia Inorganic materials 0.000 claims 2
- 240000000111 Saccharum officinarum Species 0.000 claims 1
- 235000007201 Saccharum officinarum Nutrition 0.000 claims 1
- 206010058990 Venous occlusion Diseases 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 210000003161 choroid Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 102100034608 Angiopoietin-2 Human genes 0.000 abstract description 19
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 abstract description 13
- 101000955962 Homo sapiens Vacuolar protein sorting-associated protein 51 homolog Proteins 0.000 abstract description 2
- 210000001508 eye Anatomy 0.000 description 139
- 238000011160 research Methods 0.000 description 121
- 239000000825 pharmaceutical preparation Substances 0.000 description 106
- 229940126534 drug product Drugs 0.000 description 44
- 230000000694 effects Effects 0.000 description 41
- 239000008186 active pharmaceutical agent Substances 0.000 description 33
- 229940088679 drug related substance Drugs 0.000 description 33
- 238000013534 fluorescein angiography Methods 0.000 description 26
- 238000012014 optical coherence tomography Methods 0.000 description 22
- 238000003860 storage Methods 0.000 description 22
- 230000006641 stabilisation Effects 0.000 description 20
- 238000011105 stabilization Methods 0.000 description 20
- 238000011156 evaluation Methods 0.000 description 16
- 238000007710 freezing Methods 0.000 description 16
- 230000008014 freezing Effects 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 238000003756 stirring Methods 0.000 description 13
- 238000012384 transportation and delivery Methods 0.000 description 13
- 229910052721 tungsten Inorganic materials 0.000 description 13
- 239000010937 tungsten Substances 0.000 description 13
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical class OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 229920001971 elastomer Polymers 0.000 description 12
- 230000004438 eyesight Effects 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 230000002776 aggregation Effects 0.000 description 11
- 238000004220 aggregation Methods 0.000 description 11
- 230000033115 angiogenesis Effects 0.000 description 11
- 239000011521 glass Substances 0.000 description 11
- 230000004410 intraocular pressure Effects 0.000 description 11
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 210000002189 macula lutea Anatomy 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 231100000682 maximum tolerated dose Toxicity 0.000 description 9
- -1 polyoxyethylene Polymers 0.000 description 9
- 150000005846 sugar alcohols Chemical class 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- 201000004569 Blindness Diseases 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 229940076783 lucentis Drugs 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 230000004393 visual impairment Effects 0.000 description 7
- 230000002411 adverse Effects 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 239000003433 contraceptive agent Substances 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- 239000006184 cosolvent Substances 0.000 description 6
- 210000004602 germ cell Anatomy 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000012760 heat stabilizer Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 239000013558 reference substance Substances 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000002601 radiography Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000003595 spectral effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000002146 bilateral effect Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 238000011262 co‐therapy Methods 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 229950002697 nesvacumab Drugs 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 229940071643 prefilled syringe Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 238000012453 sprague-dawley rat model Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 230000004304 visual acuity Effects 0.000 description 4
- 238000011179 visual inspection Methods 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 3
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 3
- 208000003164 Diplopia Diseases 0.000 description 3
- 241001411320 Eriogonum inflatum Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 241000220324 Pyrus Species 0.000 description 3
- 208000017442 Retinal disease Diseases 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 3
- 102100038968 WAP four-disulfide core domain protein 1 Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 210000002159 anterior chamber Anatomy 0.000 description 3
- 102000025171 antigen binding proteins Human genes 0.000 description 3
- 108091000831 antigen binding proteins Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229940124558 contraceptive agent Drugs 0.000 description 3
- 230000002254 contraceptive effect Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 235000021017 pears Nutrition 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229940034785 sutent Drugs 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 238000002562 urinalysis Methods 0.000 description 3
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000004425 Makrolon Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004155 blood-retinal barrier Anatomy 0.000 description 2
- 230000004378 blood-retinal barrier Effects 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 229920005549 butyl rubber Polymers 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000000533 capillary isoelectric focusing Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000012395 formulation development Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000013628 high molecular weight specie Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 231100000327 ocular toxicity Toxicity 0.000 description 2
- 230000010494 opalescence Effects 0.000 description 2
- 238000002577 ophthalmoscopy Methods 0.000 description 2
- 210000003733 optic disk Anatomy 0.000 description 2
- ORMNNUPLFAPCFD-DVLYDCSHSA-M phenethicillin potassium Chemical compound [K+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C(C)OC1=CC=CC=C1 ORMNNUPLFAPCFD-DVLYDCSHSA-M 0.000 description 2
- 230000000649 photocoagulation Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000029983 protein stabilization Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000004233 retinal vasculature Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000006459 vascular development Effects 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 239000012905 visible particle Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- KKEBXNMGHUCPEZ-UHFFFAOYSA-N 4-phenyl-1-(2-sulfanylethyl)imidazolidin-2-one Chemical compound N1C(=O)N(CCS)CC1C1=CC=CC=C1 KKEBXNMGHUCPEZ-UHFFFAOYSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 101710105077 Agglutinin-1 Proteins 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 101150048336 Flt1 gene Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 101150088608 Kdr gene Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 241000218194 Laurales Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000282566 Macaca arctoides Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010061137 Ocular toxicity Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920002508 Poloxamer 181 Polymers 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- 229920002651 Polysorbate 85 Polymers 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010044245 Toxic optic neuropathy Diseases 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000034698 Vitreous haemorrhage Diseases 0.000 description 1
- 206010047663 Vitritis Diseases 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000000587 angiogenesis modulating agent Substances 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940015979 epipen Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000007684 eye toxicity Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 229940062714 humalog mix Drugs 0.000 description 1
- 102000047825 human ANGPT2 Human genes 0.000 description 1
- 208000013653 hyalitis Diseases 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 206010023683 lagophthalmos Diseases 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940092110 macugen Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000008720 membrane thickening Effects 0.000 description 1
- 238000012269 metabolic engineering Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229940085692 poloxamer 181 Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 229940113171 polysorbate 85 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 230000004281 retinal morphology Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002301 subretinal fluid Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 208000000318 vitreous detachment Diseases 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462084003P | 2014-11-25 | 2014-11-25 | |
| US62/084,003 | 2014-11-25 | ||
| US201562147232P | 2015-04-14 | 2015-04-14 | |
| US62/147,232 | 2015-04-14 | ||
| US14/943,490 | 2015-11-17 | ||
| US14/943,490 US20160144025A1 (en) | 2014-11-25 | 2015-11-17 | Methods and formulations for treating vascular eye diseases |
| PCT/US2015/061543 WO2016085750A1 (en) | 2014-11-25 | 2015-11-19 | Methods and formulations for treating vascular eye diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107001457A true CN107001457A (zh) | 2017-08-01 |
Family
ID=56009149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580063632.5A Pending CN107001457A (zh) | 2014-11-25 | 2015-11-19 | 用于治疗血管性眼病的方法和制剂 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20160144025A1 (enExample) |
| EP (1) | EP3224278A4 (enExample) |
| JP (2) | JP2017536414A (enExample) |
| KR (1) | KR20170087950A (enExample) |
| CN (1) | CN107001457A (enExample) |
| AU (1) | AU2015353838A1 (enExample) |
| BR (1) | BR112017009807A2 (enExample) |
| CA (1) | CA2968522A1 (enExample) |
| CL (1) | CL2017001188A1 (enExample) |
| CO (1) | CO2017004715A2 (enExample) |
| EA (1) | EA201791168A1 (enExample) |
| IL (1) | IL252159B (enExample) |
| MA (2) | MA41028A (enExample) |
| MX (1) | MX2017006129A (enExample) |
| PE (1) | PE20170900A1 (enExample) |
| PH (1) | PH12017500834A1 (enExample) |
| SG (1) | SG11201703609UA (enExample) |
| WO (1) | WO2016085750A1 (enExample) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109598628A (zh) * | 2018-11-30 | 2019-04-09 | 平安医疗健康管理股份有限公司 | 医保欺诈行为的识别方法、装置、设备及可读存储介质 |
| CN110423281A (zh) * | 2019-07-31 | 2019-11-08 | 成都金唯科生物科技有限公司 | 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物 |
| WO2019214551A1 (zh) * | 2018-05-08 | 2019-11-14 | 华博生物医药技术（上海）有限公司 | 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂 |
| CN111465407A (zh) * | 2017-11-30 | 2020-07-28 | 瑞泽恩制药公司 | 使用vegf拮抗剂治疗生血管性眼病 |
| CN111699004A (zh) * | 2018-02-06 | 2020-09-22 | 豪夫迈·罗氏有限公司 | 眼科疾病的治疗 |
| WO2021185051A1 (zh) * | 2020-03-19 | 2021-09-23 | 浙江道尔生物科技有限公司 | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 |
| WO2021259200A1 (zh) * | 2020-06-22 | 2021-12-30 | 信达生物制药(苏州)有限公司 | 抗ang-2抗体及其用途 |
| CN115398559A (zh) * | 2020-04-29 | 2022-11-25 | 诺华股份有限公司 | 用于评估患者眼睛中疾病或病症的活动水平的计算机实施的系统和方法 |
| CN116056688A (zh) * | 2020-07-24 | 2023-05-02 | 盼展生物技术有限公司 | 眼用液体组合物 |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2633574T3 (es) | 2005-03-25 | 2017-09-22 | Regeneron Pharmaceuticals, Inc. | Formulaciones de antagonistas de VEGF |
| AU2007237096C1 (en) | 2006-04-07 | 2012-12-13 | EyePoint Pharmaceuticals, Inc. | Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof |
| PT2944306T (pt) | 2006-06-16 | 2021-02-15 | Regeneron Pharma | Formulações antagonistas de vegf adequadas para administração intravitreal |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| CN105412094A (zh) | 2009-07-06 | 2016-03-23 | 爱尔皮奥治疗有限公司 | 用于防止癌细胞转移的化合物、组合物和方法 |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
| HK1218071A1 (zh) | 2013-02-21 | 2017-02-03 | Rsem, Limited Partnership | Sema3a在预防和治疗眼渗透性过高症中的抑制 |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| US11104730B2 (en) | 2013-11-20 | 2021-08-31 | Regeneren Pharmaceuticals, Inc. | Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors |
| EP3116503A4 (en) | 2014-03-14 | 2017-08-23 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| TWI738632B (zh) | 2014-11-07 | 2021-09-11 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| JP6726734B2 (ja) * | 2015-03-26 | 2020-07-22 | アイコー，エルエルシー | 画像解析のためのシステム |
| ES2981607T3 (es) | 2015-09-23 | 2024-10-09 | Eyepoint Pharmaceuticals Inc | Activadores de Tie-2 para uso en el tratamiento de la presión intraocular |
| AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| AU2017299581B2 (en) | 2016-07-20 | 2024-05-23 | EyePoint Pharmaceuticals, Inc. | Humanized monoclonal antibodies that target ve-ptp (hptp-β) |
| US20200056186A1 (en) | 2016-09-22 | 2020-02-20 | Rsem, Limited Partnership | Compositions comprising sasp modulators and senescence attenuators and uses thereof for modulating cellular senescence |
| EP3527225A4 (en) * | 2016-10-12 | 2020-06-10 | Daiichi Sankyo Company, Limited | COMPOSITION WITH ANTI-ROBO4 ANTIBODIES AND OTHER AGENTS |
| JP7161494B2 (ja) * | 2017-05-06 | 2022-10-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｐｌｎｒアンタゴニストおよびｖｅｇｆ阻害剤によって眼疾患を治療する方法 |
| KR102798461B1 (ko) * | 2017-08-18 | 2025-04-18 | 리제너론 파마슈티칼스 인코포레이티드 | 샘플 매트릭스에서 단백질 변이체를 분석하기 위한 이미지 모세관 등전 집속 |
| CA3189025A1 (en) * | 2017-12-22 | 2019-06-27 | Samsung Bioepis Co., Ltd. | Liquid composition comprising vegf antagonist |
| SG11202007130RA (en) | 2018-01-26 | 2020-08-28 | Univ California | Methods and compositions for treatment of angiogenic disorders using anti-vegf agents |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| WO2019173767A1 (en) * | 2018-03-08 | 2019-09-12 | Coherus Biosciences Inc. | Stable aqueous formulations of aflibercept |
| US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| BR112020022610A2 (pt) | 2018-05-10 | 2021-02-09 | Regeneron Pharmaceuticals, Inc. | proteína de fusão de receptor de vegf de alta concentração que contém formulações |
| JP7249060B2 (ja) * | 2018-08-17 | 2023-03-30 | トリカン・バイオテクノロジー・カンパニー・リミテッド | 抗血管新生融合タンパク質およびその使用 |
| MX2021007393A (es) | 2018-12-18 | 2021-09-23 | Novartis Ag | Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf. |
| KR102735988B1 (ko) | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| AU2020264969B2 (en) | 2019-04-29 | 2025-06-05 | EyePoint Pharmaceuticals, Inc. | Tie-2 activators targeting the schlemm's canal |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CA3168512A1 (en) | 2019-11-25 | 2021-06-03 | Napoleone Ferrara | Long-acting vegf inhibitors for intraocular neovascularization |
| AU2021268026A1 (en) | 2020-05-08 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005072772A1 (en) * | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| WO2007089445A2 (en) * | 2006-01-27 | 2007-08-09 | Amgen Inc. | Ang2 and vegf inhibitor combinations |
| CN101478949A (zh) * | 2006-06-16 | 2009-07-08 | 瑞泽恩制药公司 | 适合玻璃体内施用的vegf拮抗剂的制剂 |
| CN102458471A (zh) * | 2009-05-28 | 2012-05-16 | 葛兰素集团有限公司 | 用于治疗或预防眼病的TNFα拮抗剂和VEGF拮抗剂的组合 |
| CN102549015A (zh) * | 2009-07-29 | 2012-07-04 | 瑞泽恩制药公司 | 针对人血管生成素-2的高亲和力人抗体 |
| US20130186797A1 (en) * | 2012-01-23 | 2013-07-25 | Regeneron Pharmaceuticals, Inc. | Stabilized Formulations Containing Anti-Ang2 Antibodies |
| US20140017244A1 (en) * | 2012-07-13 | 2014-01-16 | Roche Glycart Ag | Bispecific Anti-VEGF/Anti-ANG-2 Antibodies and their use in the Treatment of Ocular Vascular Diseases |
| CN103533950A (zh) * | 2011-01-13 | 2014-01-22 | 瑞泽恩制药公司 | Vegf拮抗剂在治疗血管生成眼病中的用途 |
| CN106062004A (zh) * | 2013-12-17 | 2016-10-26 | 科马布有限公司 | 人靶标 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| CA2665956A1 (en) * | 2009-05-07 | 2010-11-07 | Samir Patel | Combination treatment for ocular diseases |
| US8980268B2 (en) * | 2009-07-29 | 2015-03-17 | Regeneron Pharamceuticals, Inc. | Methods for treating cancer by administering an anti-Ang-2 antibody |
| US20120189635A1 (en) * | 2009-07-29 | 2012-07-26 | Regeneron Pharmaceuticals, Inc. | Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2) |
| TWI426920B (zh) * | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| CA2893767C (en) * | 2012-12-05 | 2022-11-08 | Novartis Ag | Compositions and methods for antibodies targeting epo |
| JO3405B1 (ar) * | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| RU2676303C2 (ru) * | 2013-07-11 | 2018-12-27 | Новартис Аг | Использование антагониста vegf для лечения ретролентальной фиброплазии |
| US9914769B2 (en) * | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
-
2015
- 2015-11-17 US US14/943,490 patent/US20160144025A1/en not_active Abandoned
- 2015-11-18 MA MA041028A patent/MA41028A/fr unknown
- 2015-11-19 CA CA2968522A patent/CA2968522A1/en not_active Abandoned
- 2015-11-19 BR BR112017009807A patent/BR112017009807A2/pt not_active IP Right Cessation
- 2015-11-19 WO PCT/US2015/061543 patent/WO2016085750A1/en not_active Ceased
- 2015-11-19 AU AU2015353838A patent/AU2015353838A1/en not_active Abandoned
- 2015-11-19 EA EA201791168A patent/EA201791168A1/ru unknown
- 2015-11-19 SG SG11201703609UA patent/SG11201703609UA/en unknown
- 2015-11-19 KR KR1020177017473A patent/KR20170087950A/ko not_active Withdrawn
- 2015-11-19 MX MX2017006129A patent/MX2017006129A/es unknown
- 2015-11-19 PE PE2017000901A patent/PE20170900A1/es unknown
- 2015-11-19 MA MA40306A patent/MA40306A1/fr unknown
- 2015-11-19 EP EP15862329.8A patent/EP3224278A4/en not_active Withdrawn
- 2015-11-19 JP JP2017545861A patent/JP2017536414A/ja active Pending
- 2015-11-19 CN CN201580063632.5A patent/CN107001457A/zh active Pending
-
2016
- 2016-12-06 US US15/370,896 patent/US20170080086A1/en not_active Abandoned
-
2017
- 2017-05-05 PH PH12017500834A patent/PH12017500834A1/en unknown
- 2017-05-08 IL IL252159A patent/IL252159B/en active IP Right Grant
- 2017-05-10 CL CL2017001188A patent/CL2017001188A1/es unknown
- 2017-05-10 CO CONC2017/0004715A patent/CO2017004715A2/es unknown
-
2018
- 2018-12-28 US US16/235,221 patent/US11071780B2/en active Active
-
2020
- 2020-12-04 JP JP2020201473A patent/JP2021046431A/ja active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005072772A1 (en) * | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| WO2007089445A2 (en) * | 2006-01-27 | 2007-08-09 | Amgen Inc. | Ang2 and vegf inhibitor combinations |
| CN101478949A (zh) * | 2006-06-16 | 2009-07-08 | 瑞泽恩制药公司 | 适合玻璃体内施用的vegf拮抗剂的制剂 |
| CN102458471A (zh) * | 2009-05-28 | 2012-05-16 | 葛兰素集团有限公司 | 用于治疗或预防眼病的TNFα拮抗剂和VEGF拮抗剂的组合 |
| CN102549015A (zh) * | 2009-07-29 | 2012-07-04 | 瑞泽恩制药公司 | 针对人血管生成素-2的高亲和力人抗体 |
| CN103533950A (zh) * | 2011-01-13 | 2014-01-22 | 瑞泽恩制药公司 | Vegf拮抗剂在治疗血管生成眼病中的用途 |
| US20130186797A1 (en) * | 2012-01-23 | 2013-07-25 | Regeneron Pharmaceuticals, Inc. | Stabilized Formulations Containing Anti-Ang2 Antibodies |
| CN104169299B (zh) * | 2012-01-23 | 2018-06-05 | 瑞泽恩制药公司 | 含抗Ang-2 抗体的稳定化制剂 |
| US20140017244A1 (en) * | 2012-07-13 | 2014-01-16 | Roche Glycart Ag | Bispecific Anti-VEGF/Anti-ANG-2 Antibodies and their use in the Treatment of Ocular Vascular Diseases |
| CN106062004A (zh) * | 2013-12-17 | 2016-10-26 | 科马布有限公司 | 人靶标 |
Non-Patent Citations (3)
| Title |
|---|
| MARK RATNER等: "Next-generation AMD drugs to wed blockbusters", 《NATURE BIOTECHNOLOGY》 * |
| REGENERON PHARMACEUTICALS: "NCT01997164", 《HTTPS://CLINICALTRIALS.GOV/CT2/HISTORY/NCT01997164?V_1=VIEW#STUDYPAGETOP》 * |
| 徐欢等: "湿性年龄相关性黄斑变性的新药研发进展", 《中国新药杂志》 * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111465407A (zh) * | 2017-11-30 | 2020-07-28 | 瑞泽恩制药公司 | 使用vegf拮抗剂治疗生血管性眼病 |
| CN111699004A (zh) * | 2018-02-06 | 2020-09-22 | 豪夫迈·罗氏有限公司 | 眼科疾病的治疗 |
| WO2019214551A1 (zh) * | 2018-05-08 | 2019-11-14 | 华博生物医药技术（上海）有限公司 | 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂 |
| CN109598628A (zh) * | 2018-11-30 | 2019-04-09 | 平安医疗健康管理股份有限公司 | 医保欺诈行为的识别方法、装置、设备及可读存储介质 |
| CN110423281A (zh) * | 2019-07-31 | 2019-11-08 | 成都金唯科生物科技有限公司 | 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物 |
| CN110423281B (zh) * | 2019-07-31 | 2021-04-30 | 成都金唯科生物科技有限公司 | 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物 |
| WO2021185051A1 (zh) * | 2020-03-19 | 2021-09-23 | 浙江道尔生物科技有限公司 | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 |
| CN113493519A (zh) * | 2020-03-19 | 2021-10-12 | 浙江道尔生物科技有限公司 | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 |
| CN113493519B (zh) * | 2020-03-19 | 2022-12-27 | 浙江道尔生物科技有限公司 | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 |
| CN115398559A (zh) * | 2020-04-29 | 2022-11-25 | 诺华股份有限公司 | 用于评估患者眼睛中疾病或病症的活动水平的计算机实施的系统和方法 |
| WO2021259200A1 (zh) * | 2020-06-22 | 2021-12-30 | 信达生物制药(苏州)有限公司 | 抗ang-2抗体及其用途 |
| CN116056688A (zh) * | 2020-07-24 | 2023-05-02 | 盼展生物技术有限公司 | 眼用液体组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CL2017001188A1 (es) | 2017-11-24 |
| US20170080086A1 (en) | 2017-03-23 |
| MA40306A1 (fr) | 2019-03-29 |
| CO2017004715A2 (es) | 2017-09-20 |
| MX2017006129A (es) | 2018-04-10 |
| CA2968522A1 (en) | 2016-06-02 |
| US20160144025A1 (en) | 2016-05-26 |
| JP2021046431A (ja) | 2021-03-25 |
| SG11201703609UA (en) | 2017-06-29 |
| WO2016085750A1 (en) | 2016-06-02 |
| MA41028A (fr) | 2017-10-03 |
| EP3224278A4 (en) | 2018-07-11 |
| PH12017500834A1 (en) | 2017-10-30 |
| AU2015353838A1 (en) | 2017-06-08 |
| EA201791168A1 (ru) | 2017-09-29 |
| PE20170900A1 (es) | 2017-07-12 |
| IL252159B (en) | 2021-03-25 |
| BR112017009807A2 (pt) | 2018-02-27 |
| EP3224278A1 (en) | 2017-10-04 |
| US20190117767A1 (en) | 2019-04-25 |
| KR20170087950A (ko) | 2017-07-31 |
| US11071780B2 (en) | 2021-07-27 |
| JP2017536414A (ja) | 2017-12-07 |
| IL252159A0 (en) | 2017-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107001457A (zh) | 用于治疗血管性眼病的方法和制剂 | |
| US20250268983A1 (en) | Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders | |
| AU2022275786B2 (en) | Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders | |
| EP4245313A1 (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| US20240024420A1 (en) | Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders | |
| JP2022547537A (ja) | 眼疾患を治療するための方法 | |
| EP4480491A1 (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| Sharma et al. | Ophthalmic product development for biologics | |
| HK40119109A (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| HK40099475A (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| CA3190726A1 (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| HK1241908A1 (en) | Methods and formulations for treating vascular eye diseases | |
| EA046420B1 (ru) | Применение антагониста vegf для лечения ангиогенных глазных заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1241908 Country of ref document: HK |
|
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170801 |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1241908 Country of ref document: HK |